Richard Joseph, assistant professor of medical oncology at Mayo Clinic in Jacksonville, Florida, explains how treatment outcomes for metastatic melanoma have grown in the past few years.
Richard Joseph, assistant professor of medical oncology at Mayo Clinic in Jacksonville, Florida, explains how treatment outcomes for metastatic melanoma have grown in the past few years.
Prior to drug approvals in 2011, Joseph says the median survival rate for patients with metastatic melanoma was approximately nine months. Today, it is more than 20 months, mainly due to approvals of Yervoy (iplilimumab), BRAF inhibitors and PD-1 inhibitors. This survival rate is found to be impressive, as no increase had been seen in the 30 years prior to 2011.
Olivia Munn Discusses Breast Cancer, Christine Brinkley Diagnosed With Basal Cell Carcinoma and More
March 15th 2024From Oliva Munn and Christine Brinkley discussing their cancer to Donnie Iris returning to the stage after his experience with the disease, here is what’s happening in the oncology space this week.
Read More